menu
    • menu
    [{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhalation Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP50","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Inhaled dry powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Voriconazole","moa":"CYP450","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Public Offering","leadProduct":"Voriconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0.01,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.01,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"Eugia Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Voriconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Eugia Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Eugia Pharma \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Eugia Pharma \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Voriconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder for Inhalation","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"TFF Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Voriconazole","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"TFF Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Powder","sponsorNew":"TFF Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"TFF Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for (+/-)-Voriconazole

    Menu

    (+/-)-Voriconazole

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Updates Data from Clinical Programs on Tacrolimus and Voriconazole

                            Details : TFF VORI (voriconazole) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for invasive pulmonary aspergillosis & allergic bronchopulmonary aspergillosis.

                            Brand Name : TFF VORI

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 27, 2024

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Inc. and Uniphar Durbin Ireland Ltd. Announce the Opening of an Expanded Access Program fo...

                            Details : TFF VORI (voriconazole inhalation powder) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole in development for the treatment and prevention of invasive pulmonary aspergillosis (IPA), a severe fungal pulmonary disease.

                            Brand Name : TFF Vori

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 31, 2023

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eugia Pharma

                            India arrow
                            PharmaVenue
                            Not Confirmed

                            Eugia Pharma

                            India arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Eugia Pharma Receives USFDA Approval for Voriconazole for Injection, 200 mg/Vial Single-Dose Vial

                            Details : Voriconazole is a triazole antifungal agent. The primary mode of action of voriconazole is the inhibition of fungal cytochrome P-450-mediated 14 alpha-lanosterol demethylation, an essential step in fungal ergosterol biosynthesis.

                            Brand Name : Vfend-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 02, 2023

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : JonesTrading Institutional Services

                            Deal Size : $12.3 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Announces Closing of $12.3 Million Public Offering

                            Details : TFF Pharmaceuticals intends to use the net proceeds from the offering for clinical trials, research and development, working capital and general corporate purposes.

                            Brand Name : TFF VORI

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 29, 2022

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : JonesTrading Institutional Services

                            Deal Size : $12.3 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Announces Second Patient Successfully Treated with Voriconazole Inhalation Powder Through ...

                            Details : TFF VORI (voriconazole) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA).

                            Brand Name : TFF VORI

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 01, 2022

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Announces Program Updates for Voriconazole Inhaled Powder and Tacrolimus Inhaled Powder Cl...

                            Details : TFF VORI (voriconazole) is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA).

                            Brand Name : TFF VORI

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 01, 2022

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Announces Presentation of Patient Data with Voriconazole Inhalation Powder (TFF VORI) at t...

                            Details : TFF VORI is a next-generation, direct-to-lung, inhaled dry powder formulation of voriconazole for the treatment and prevention of Invasive Pulmonary Aspergillosis (IPA).

                            Brand Name : TFF VORI

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 08, 2022

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Provides Update on Clinical Development Programs

                            Details : The Phase 1 clinical trial of Voriconazole Inhalation Powder for the treatment of invasive pulmonary aspergillosis (IPA) has been successfully completed and comprehensive safety and pharmacokinetic data is now available following delivery of the clinical...

                            Brand Name : TFF VORI

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 04, 2021

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Announces Topline Results of Voriconazole Inhalation Powder Phase 1 Clinical Trial

                            Details : Dosing of the Voriconazole Inhalation Powder resulted in plasma levels greater than drug levels achieved in published reports for dose levels that were efficacious in IPA patients.

                            Brand Name : TFF VORI

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            September 15, 2020

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed

                            TFF Pharmaceuticals

                            U.S.A arrow
                            PharmaVenue
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical Trial

                            Details : Voriconazole Inhalation Powder is a next-generation, direct-to-lung, inhaled dry powder version of Voriconazole, generally considered to be the most effective antifungal drug for treating Invasive Pulmonary Aspergillosis (IPA).

                            Brand Name : TFF VORI

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 30, 2020

                            Lead Product(s) : Voriconazole

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth